LEXARIA BIOSCIENCE CORP. Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
LEXARIA BIOSCIENCE CORP. (LEXX) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of $23.86 thousand for the 9-month period ending 2026-05-31, per its 10-Q filed 2026-07-13.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-07-13
- LEXARIA BIOSCIENCE CORP. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-11-30 was -$5.74K.
- LEXARIA BIOSCIENCE CORP. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-11-30 was -$3.17K, a 172.62% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-11-30 was $4.37K.
- LEXARIA BIOSCIENCE CORP. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2022-11-30 was $0.00.
- LEXARIA BIOSCIENCE CORP. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was -$50.52K.
- LEXARIA BIOSCIENCE CORP. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was -$19.82K.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|
| 2026-05-31 | $23.86K 10-Q · filed 2026-07-13 | |||
| 2026-02-28 | $14.89K 10-Q · filed 2026-04-13 | |||
| 2025-11-30 | -$5.74K 10-Q · filed 2026-01-13 | |||
| 2025-08-31 | -$50.52K 10-K · filed 2025-11-28 | |||
| 2025-05-31 | -$61.26K 10-Q · filed 2026-07-13 | |||
| 2025-02-28 | -$98.43K 10-Q · filed 2026-04-13 | |||
| 2024-11-30 | -$3.17K 10-Q · filed 2026-01-13 | |||
| 2024-08-31 | -$19.82K 10-K · filed 2025-11-28 | |||
| 2024-05-31 | -$21.87K 10-Q · filed 2025-07-14 | |||
| 2024-02-29 | -$20.63K 10-Q · filed 2025-04-14 | |||
| 2023-11-30 | $4.37K 10-Q · filed 2025-01-10 | |||
| 2023-05-31 | $0.00 10-Q · filed 2024-07-12 | |||
| 2023-02-28 | $0.00 10-Q · filed 2024-04-09 | |||
| 2022-11-30 | $0.00 10-Q · filed 2024-01-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |